JNS: The intranasal Covid-19 vaccine— iNCOVACC (BBV154), developed by Bharat Biotech, received approval from the ministry of health on Friday to be added to the vaccination programme as a booster dose for people aged 18 and up.
The approval of the vaccine comes at a time when there has been an increase in the number of cases of Covid in China and other countries.
The vaccination would not require any needles and will be offered at private clinics. On Friday evening, it will be presented on the Co-WIN platform for the first time. Presently, five vaccines were listed in the Co-Win portal: Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, the Russian Sputnik V, and Biological E Ltd’s Corbevax.
Notably, on 6 September, iNCOVACC got the approval from the Drugs Controller General of India for “Restricted Use in Emergency Situation” for patients aged 18 and older.
